The Latin America, Middle East and Africa Lymphoma Therapeutics Market should witness market growth of 11.4% CAGR during the forecast period (2023-2029).
Targeted therapies are gaining attention as a potential treatment for lymphoma. Researchers' enhanced understanding of lymphoma cells has facilitated the development of novel drugs that specifically target distinct components of these cells. Targeted drugs are distinct from conventional chemotherapy drugs as they specifically target certain cells rather than attacking rapidly dividing cells. These pharmaceuticals are currently utilized for certain forms of NHL.
Currently, there is significant progress being made by scientists in comprehending the alterations in DNA within normal lymphocytes that may lead to the formation of lymphoma cells. Therefore, stem cell transplant is a technique that can be utilized in business. In addition, certain monoclonal antibodies recently created for lymphoma treatment could aid in eliminating residual cells.
Furthermore, researchers are currently investigating the efficacy of non-myeloablative stem cell transplants with reduced intensity for individuals diagnosed with lymphoma. CAR T-cell therapy is a viable technique for consideration. This procedure involves extracting T-cells from the patient's blood and modifying them in the laboratory to express chimeric antigen receptors (CARs) on their surface as part of the treatment. The receptors can bind with proteins on the lymphoma cells' surface and initiate a targeted immune response to eliminate them. Thus, such advancements in lymphoma therapeutics are expected to aid the market growth during the projected period.
In 2019, the third-leading cause of death in the UAE was identified as accounting for 10% of all mortality, following cardiovascular disease and injuries. The UAE has set a goal to decrease cancer mortality by approximately 18% by 2025. The UAE's national agenda includes reducing cancer-related deaths as a key performance indicator, in line with its commitment to providing world-class healthcare. Hence, with obesity, the chances of lymphoma prevalence in the general public are expected to increase, and the commitment of the government to decrease and effectively treat cancer cases is anticipated to give rise to the demand and availability for lymphoma therapeutics, aiding the market growth in the region.
The Brazil market dominated the LAMEA Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $449.9 million by 2029. The Argentina market is exhibiting a CAGR of 12% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 11.1% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
Targeted therapies are gaining attention as a potential treatment for lymphoma. Researchers' enhanced understanding of lymphoma cells has facilitated the development of novel drugs that specifically target distinct components of these cells. Targeted drugs are distinct from conventional chemotherapy drugs as they specifically target certain cells rather than attacking rapidly dividing cells. These pharmaceuticals are currently utilized for certain forms of NHL.
Currently, there is significant progress being made by scientists in comprehending the alterations in DNA within normal lymphocytes that may lead to the formation of lymphoma cells. Therefore, stem cell transplant is a technique that can be utilized in business. In addition, certain monoclonal antibodies recently created for lymphoma treatment could aid in eliminating residual cells.
Furthermore, researchers are currently investigating the efficacy of non-myeloablative stem cell transplants with reduced intensity for individuals diagnosed with lymphoma. CAR T-cell therapy is a viable technique for consideration. This procedure involves extracting T-cells from the patient's blood and modifying them in the laboratory to express chimeric antigen receptors (CARs) on their surface as part of the treatment. The receptors can bind with proteins on the lymphoma cells' surface and initiate a targeted immune response to eliminate them. Thus, such advancements in lymphoma therapeutics are expected to aid the market growth during the projected period.
In 2019, the third-leading cause of death in the UAE was identified as accounting for 10% of all mortality, following cardiovascular disease and injuries. The UAE has set a goal to decrease cancer mortality by approximately 18% by 2025. The UAE's national agenda includes reducing cancer-related deaths as a key performance indicator, in line with its commitment to providing world-class healthcare. Hence, with obesity, the chances of lymphoma prevalence in the general public are expected to increase, and the commitment of the government to decrease and effectively treat cancer cases is anticipated to give rise to the demand and availability for lymphoma therapeutics, aiding the market growth in the region.
The Brazil market dominated the LAMEA Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $449.9 million by 2029. The Argentina market is exhibiting a CAGR of 12% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 11.1% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
Scope of the Study
By Treatment Type
- Immune Therapy
- Target Therapy
- Chemotherapy
- Radiation Therapy
By Disease Type
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
By Route of Administration
- Injectable
- Oral Route
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Lymphoma Therapeutics Market, by Treatment Type
1.4.2 LAMEA Lymphoma Therapeutics Market, by Disease Type
1.4.3 LAMEA Lymphoma Therapeutics Market, by Route of Administration
1.4.4 LAMEA Lymphoma Therapeutics Market, by Distribution Channel
1.4.5 LAMEA Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. LAMEA Lymphoma Therapeutics Market by Treatment Type
4.1 LAMEA Immune Therapy Market by Country
4.2 LAMEA Target Therapy Market by Country
4.3 LAMEA Chemotherapy Market by Country
4.4 LAMEA Radiation Therapy Market by Country
Chapter 5. LAMEA Lymphoma Therapeutics Market by Disease Type
5.1 LAMEA Non-Hodgkin Lymphoma Market by Country
5.2 LAMEA Hodgkin Lymphoma Market by Country
Chapter 6. LAMEA Lymphoma Therapeutics Market by Route of Administration
6.1 LAMEA Injectable Market by Country
6.2 LAMEA Oral Route Market by Country
Chapter 7. LAMEA Lymphoma Therapeutics Market by Distribution Channel
7.1 LAMEA Hospital Pharmacies Market by Country
7.2 LAMEA Retail Pharmacies Market by Country
7.3 LAMEA Others Market by Country
Chapter 8. LAMEA Lymphoma Therapeutics Market by Country
8.1 Brazil Lymphoma Therapeutics Market
8.1.1 Brazil Lymphoma Therapeutics Market by Treatment Type
8.1.2 Brazil Lymphoma Therapeutics Market by Disease Type
8.1.3 Brazil Lymphoma Therapeutics Market by Route of Administration
8.1.4 Brazil Lymphoma Therapeutics Market by Distribution Channel
8.2 Argentina Lymphoma Therapeutics Market
8.2.1 Argentina Lymphoma Therapeutics Market by Treatment Type
8.2.2 Argentina Lymphoma Therapeutics Market by Disease Type
8.2.3 Argentina Lymphoma Therapeutics Market by Route of Administration
8.2.4 Argentina Lymphoma Therapeutics Market by Distribution Channel
8.3 UAE Lymphoma Therapeutics Market
8.3.1 UAE Lymphoma Therapeutics Market by Treatment Type
8.3.2 UAE Lymphoma Therapeutics Market by Disease Type
8.3.3 UAE Lymphoma Therapeutics Market by Route of Administration
8.3.4 UAE Lymphoma Therapeutics Market by Distribution Channel
8.4 Saudi Arabia Lymphoma Therapeutics Market
8.4.1 Saudi Arabia Lymphoma Therapeutics Market by Treatment Type
8.4.2 Saudi Arabia Lymphoma Therapeutics Market by Disease Type
8.4.3 Saudi Arabia Lymphoma Therapeutics Market by Route of Administration
8.4.4 Saudi Arabia Lymphoma Therapeutics Market by Distribution Channel
8.5 South Africa Lymphoma Therapeutics Market
8.5.1 South Africa Lymphoma Therapeutics Market by Treatment Type
8.5.2 South Africa Lymphoma Therapeutics Market by Disease Type
8.5.3 South Africa Lymphoma Therapeutics Market by Route of Administration
8.5.4 South Africa Lymphoma Therapeutics Market by Distribution Channel
8.6 Nigeria Lymphoma Therapeutics Market
8.6.1 Nigeria Lymphoma Therapeutics Market by Treatment Type
8.6.2 Nigeria Lymphoma Therapeutics Market by Disease Type
8.6.3 Nigeria Lymphoma Therapeutics Market by Route of Administration
8.6.4 Nigeria Lymphoma Therapeutics Market by Distribution Channel
8.7 Rest of LAMEA Lymphoma Therapeutics Market
8.7.1 Rest of LAMEA Lymphoma Therapeutics Market by Treatment Type
8.7.2 Rest of LAMEA Lymphoma Therapeutics Market by Disease Type
8.7.3 Rest of LAMEA Lymphoma Therapeutics Market by Route of Administration
8.7.4 Rest of LAMEA Lymphoma Therapeutics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Financial Analysis
9.3.3 Research & Development Expenses
9.3.4 Recent strategies and developments:
9.3.4.1 Partnerships, Collaborations, and Agreements:
9.3.4.2 Acquisition and Mergers:
9.3.4.3 Approvals and Trials:
9.4 Bristol Myers Squibb Company
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Acquisition and Mergers:
9.4.5.2 Approvals and Trials:
9.5 Pfizer, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional & Segmental Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Approvals and Trials:
9.6 AstraZeneca PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.5.3 Approvals and Trials:
9.7 Teva Pharmaceutical Industries Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.8 Eli Lilly And Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.5.2 Approvals and Trials:
9.9 Seagen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals and Trials:
9.10. F. Hoffmann-La Roche Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
Companies Mentioned
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Methodology
LOADING...
